Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125840542 | 12584054 | 2 | F | 2016 | 20160726 | 20160722 | 20160805 | PER | US-ASTRAZENECA-2016SE71439 | ASTRAZENECA | 66.00 | YR | F | Y | 57.80000 | KG | 20160805 | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125840542 | 12584054 | 1 | PS | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | U | U | 21153 | 40 | MG | CAPSULE | QD | |||||
| 125840542 | 12584054 | 2 | SS | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | GENERIC NEXIUM, 40MG DAILY | U | U | 21153 | ||||||||
| 125840542 | 12584054 | 3 | SS | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | U | U | 21153 | 40 | MG | CAPSULE | QD | |||||
| 125840542 | 12584054 | 4 | SS | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | U | U | HF0025 | 21153 | 40 | MG | CAPSULE | BID | ||||
| 125840542 | 12584054 | 5 | SS | NEXIUM 24HR | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | U | 0 | 40 | MG | QD | |||||||
| 125840542 | 12584054 | 6 | SS | CRESTOR | ROSUVASTATIN CALCIUM | 1 | Oral | 0 | 5 | MG | TABLET | QD | |||||||
| 125840542 | 12584054 | 7 | C | SIMVASTATIN. | SIMVASTATIN | 1 | 0 | ||||||||||||
| 125840542 | 12584054 | 8 | C | INHALER | UNSPECIFIED INGREDIENT | 1 | Respiratory (inhalation) | 0 | |||||||||||
| 125840542 | 12584054 | 9 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125840542 | 12584054 | 1 | Gastrooesophageal reflux disease |
| 125840542 | 12584054 | 2 | Gastrooesophageal reflux disease |
| 125840542 | 12584054 | 3 | Gastrooesophageal reflux disease |
| 125840542 | 12584054 | 4 | Gastrooesophageal reflux disease |
| 125840542 | 12584054 | 5 | Gastrooesophageal reflux disease |
| 125840542 | 12584054 | 6 | Blood cholesterol increased |
| 125840542 | 12584054 | 7 | Blood cholesterol increased |
| 125840542 | 12584054 | 8 | Hypersensitivity |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125840542 | 12584054 | Blood cholesterol increased | |
| 125840542 | 12584054 | Blood creatine phosphokinase increased | |
| 125840542 | 12584054 | Drug ineffective for unapproved indication | |
| 125840542 | 12584054 | Dysphonia | |
| 125840542 | 12584054 | Gastrooesophageal reflux disease | |
| 125840542 | 12584054 | Glucose tolerance impaired | |
| 125840542 | 12584054 | Hypersensitivity | |
| 125840542 | 12584054 | Off label use | |
| 125840542 | 12584054 | Pain in extremity | |
| 125840542 | 12584054 | Pharyngeal erythema | |
| 125840542 | 12584054 | Product physical issue |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125840542 | 12584054 | 1 | 2003 | 0 | ||
| 125840542 | 12584054 | 2 | 2016 | 0 | ||
| 125840542 | 12584054 | 3 | 2016 | 0 | ||
| 125840542 | 12584054 | 4 | 20160617 | 0 | ||
| 125840542 | 12584054 | 5 | 2016 | 0 |